脂质代谢与非酒精性脂肪肝病概述。
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.
机构信息
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China.
出版信息
Biomed Res Int. 2020 Jul 18;2020:4020249. doi: 10.1155/2020/4020249. eCollection 2020.
Abstract
The occurrence of nonalcoholic fatty liver disease (NAFLD) is associated with major abnormalities of hepatic lipid metabolism. We propose that lipid abnormalities directly or indirectly contribute to NAFLD, especially fatty acid accumulation, arachidonic acid metabolic disturbance, and ceramide overload. The effects of lipid intake and accumulation on NAFLD and NAFLD treatment are explained with theoretical and experimental details. Overall, these findings provide further understanding of lipid metabolism in NAFLD and may lead to novel therapies.
摘要
非酒精性脂肪性肝病（NAFLD）的发生与肝脏脂质代谢的主要异常有关。我们提出脂质异常直接或间接导致 NAFLD，特别是脂肪酸积累、花生四烯酸代谢紊乱和神经酰胺过载。脂质摄入和积累对 NAFLD 和 NAFLD 治疗的影响用理论和实验细节进行了解释。总的来说，这些发现进一步了解了 NAFLD 中的脂质代谢，并可能导致新的治疗方法。
相似文献
1
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.脂质代谢与非酒精性脂肪肝病概述。
Biomed Res Int. 2020 Jul 18;2020:4020249. doi: 10.1155/2020/4020249. eCollection 2020.
2
Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.线粒体功能障碍相关的脂质变化发生在非酒精性脂肪性肝病的进展过程中。
J Lipid Res. 2018 Oct;59(10):1977-1986. doi: 10.1194/jlr.M085613. Epub 2018 Jul 24.
3
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.黄连素改善非酒精性脂肪性肝病中的糖异生和脂质代谢。
BMC Endocr Disord. 2017 Feb 28;17(1):13. doi: 10.1186/s12902-017-0165-7.
4
Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.肝促生素在非酒精性脂肪性肝病糖尿病患者中的过表达可能会促进肝脏脂质蓄积增加。
Endocr Metab Immune Disord Drug Targets. 2019;19(2):185-188. doi: 10.2174/1871530318666180716100543.
5
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 中维生素 A 代谢紊乱。
Nutrients. 2017 Dec 29;10(1):29. doi: 10.3390/nu10010029.
6
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.黄连素对非酒精性脂肪性肝病患者治疗作用的脂质谱分析
J Transl Med. 2016 Sep 15;14:266. doi: 10.1186/s12967-016-0982-x.
7
Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.下调 microRNA-130b-5p 可预防非酒精性脂肪性肝病小鼠模型中的脂质积累和胰岛素抵抗。
Am J Physiol Endocrinol Metab. 2020 Jul 1;319(1):E34-E42. doi: 10.1152/ajpendo.00528.2019. Epub 2020 Mar 31.
8
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.载脂蛋白C3蛋白并非小鼠脂肪诱导的非酒精性脂肪性肝病的诱发因素。
J Biol Chem. 2017 Mar 3;292(9):3692-3705. doi: 10.1074/jbc.M116.765917. Epub 2017 Jan 23.
9
Non-alcoholic fatty liver disease: Insights from sphingolipidomics.非酒精性脂肪性肝病：鞘脂组学的新见解。
Biochem Biophys Res Commun. 2018 Oct 7;504(3):608-616. doi: 10.1016/j.bbrc.2018.05.078. Epub 2018 May 21.
10
'Micro-managers' of hepatic lipid metabolism and NAFLD.肝脂代谢和非酒精性脂肪性肝病的“微观管理者”。
Wiley Interdiscip Rev RNA. 2015 Sep-Oct;6(5):581-93. doi: 10.1002/wrna.1295. Epub 2015 Jul 21.
引用本文的文献
1
Association between lipid accumulation product and non-alcoholic fatty liver disease with normal weight: a population-based study.脂质蓄积产物与体重正常的非酒精性脂肪性肝病之间的关联：一项基于人群的研究。
Front Med (Lausanne). 2025 Aug 20;12:1565997. doi: 10.3389/fmed.2025.1565997. eCollection 2025.
2
ScRNA-seq combined with ATAC-seq analysis to explore the metabolic balance mechanism of CCl4-induced liver inflammatory injury.单细胞RNA测序联合染色质转座酶可及性测序分析以探究四氯化碳诱导的肝脏炎性损伤的代谢平衡机制。
Front Immunol. 2025 Jun 16;16:1600685. doi: 10.3389/fimmu.2025.1600685. eCollection 2025.
3
Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease.1型糖尿病中与代谢功能障碍相关脂肪性肝病相关的代谢物扰动。
Front Endocrinol (Lausanne). 2025 Jun 3;16:1500242. doi: 10.3389/fendo.2025.1500242. eCollection 2025.
4
Inhibition of Triacylglycerol Accumulation and Oxidized Hydroperoxides in Hepatocytes by (Bulb).（鳞茎）对肝细胞中三酰甘油积累和氧化氢过氧化物的抑制作用
Antioxidants (Basel). 2025 May 29;14(6):653. doi: 10.3390/antiox14060653.
5
MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles.微小RNA-26b可预防小鼠的胃黏膜萎缩性病变，并且可以被脂质纳米颗粒有效靶向。
Elife. 2025 Apr 22;13:RP97165. doi: 10.7554/eLife.97165.
6
Kaili sour soup in alleviation of hepatic steatosis in rats via lycopene route: an experimental study.凯里酸汤通过番茄红素途径减轻大鼠肝脂肪变性的实验研究
Ann Med. 2025 Dec;57(1):2479585. doi: 10.1080/07853890.2025.2479585. Epub 2025 Apr 21.
7
The Active Components of Traditional Chinese Medicines Regulate the Multi-Target Signaling Pathways of Metabolic Dysfunction-Associated Fatty Liver Disease.中药活性成分调控代谢功能障碍相关脂肪性肝病的多靶点信号通路
Drug Des Devel Ther. 2025 Apr 9;19:2693-2715. doi: 10.2147/DDDT.S514498. eCollection 2025.
8
Non-linear relationship between triglyceride glucose index and new-onset diabetes among individuals with non-alcoholic fatty liver disease: a cohort study.非酒精性脂肪性肝病患者中甘油三酯葡萄糖指数与新发糖尿病之间的非线性关系：一项队列研究
Lipids Health Dis. 2025 Mar 15;24(1):94. doi: 10.1186/s12944-025-02518-5.
9
Passion Fruit Seed Extract Attenuates Hepatic Steatosis in Oleic Acid-Treated HepG2 Cells through Modulation of ERK1/2 and Akt Signaling Pathways.百香果籽提取物通过调节ERK1/2和Akt信号通路减轻油酸处理的HepG2细胞中的肝脂肪变性。
Cell Biochem Biophys. 2025 Sep;83(3):3249-3263. doi: 10.1007/s12013-025-01706-5. Epub 2025 Mar 1.
10
Effect of onion peel extract and quercetin at an equivalent concentration in the extract on the improvement of dyslipidemia induced by high fat diet in rats.洋葱皮提取物及提取物中同等浓度槲皮素对改善高脂饮食诱导的大鼠血脂异常的作用。
Food Sci Biotechnol. 2024 Nov 21;34(4):1045-1054. doi: 10.1007/s10068-024-01741-7. eCollection 2025 Mar.
本文引用的文献
1
Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis.体重变化和生活方式改变对非酒精性脂肪性肝病发展或缓解的影响：基于性别差异的分析。
Sci Rep. 2020 Jan 16;10(1):481. doi: 10.1038/s41598-019-57369-9.
2
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.SUMOylation 抑制剂与 FXR 激动剂协同作用抗肝纤维化。
Nat Commun. 2020 Jan 13;11(1):240. doi: 10.1038/s41467-019-14138-6.
3
Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.法尼醇X受体激活可诱导非酒精性脂肪性肝病中肝毒性1-脱氧鞘脂的降解。
Liver Int. 2020 Apr;40(4):844-859. doi: 10.1111/liv.14340. Epub 2020 Jan 8.
4
CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway.CD36 通过 AMPK 依赖性途径在肝细胞的脂噬调控中发挥负调控作用。
J Lipid Res. 2019 Apr;60(4):844-855. doi: 10.1194/jlr.M090969. Epub 2019 Jan 20.
5
Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide.酒精性和非酒精性脂肪性肝病：聚焦神经酰胺
Adv Biol Regul. 2018 Dec;70:40-50. doi: 10.1016/j.jbior.2018.11.004. Epub 2018 Nov 14.
6
Molecular pathways of nonalcoholic fatty liver disease development and progression.非酒精性脂肪性肝病发生和进展的分子途径。
Cell Mol Life Sci. 2019 Jan;76(1):99-128. doi: 10.1007/s00018-018-2947-0. Epub 2018 Oct 20.
7
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.生物活性脂质种类及其在非酒精性脂肪性肝炎进展和消退中的代谢途径。
Gastroenterology. 2018 Aug;155(2):282-302.e8. doi: 10.1053/j.gastro.2018.06.031. Epub 2018 Jun 12.
8
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.法尼醇 X 受体激活对花生四烯酸代谢、NF-κB 信号通路和肝脏炎症的影响。
Mol Pharmacol. 2018 Aug;94(2):802-811. doi: 10.1124/mol.117.111047. Epub 2018 May 9.
9
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.CD36 的棕榈酰化作用破坏游离脂肪酸代谢并促进非酒精性脂肪性肝炎中的组织炎症。
J Hepatol. 2018 Sep;69(3):705-717. doi: 10.1016/j.jhep.2018.04.006. Epub 2018 Apr 27.
10
CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance.神经酰胺合酶2单倍体不足抑制β-氧化并导致饮食诱导的脂肪性肝炎和胰岛素抵抗易感性。
Cell Metab. 2014 Nov 4;20(5):919. doi: 10.1016/j.cmet.2014.10.007.
Zotero 插件